Deciphera Pharmaceuticals, Inc. (DCPH)

Market Cap	2.20B
Revenue (ttm)	174.91M
Net Income (ttm)	-190.42M
Shares Out	86.48M
EPS (ttm)	-2.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	941,355
Open	25.47
Previous Close	25.44
Day's Range	25.44 - 25.48
52-Week Range	9.90 - 25.55
Beta	0.20
Analysts	Buy
Price Target	24.17 (-5.03%)
Earnings Date	May 10, 2024

About DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switc...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 28, 2017
• Employees: 355
• Stock Exchange: NASDAQ
• Ticker Symbol: DCPH

Financial Performance

In 2023, DCPH's revenue was $163.36 million, an increase of 21.87% compared to the previous year's $134.04 million. Losses were -$194.94 million, 8.95% more than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for DCPH stock is "Buy." The 12-month stock price forecast is $24.17, which is a decrease of -5.03% from the latest price.

Price Target

$24.17

(-5.03% downside)

Analyst Consensus: Buy